EQ vs REGN · rev $41.1M vs P/E 14, rev $14.34B
Equillium Inc (EQ) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Equillium Inc (EQ) is a biotechnology company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported EQ revenue for 2024-12-31 was $41.1M. Net income was -$8.1M. Revenue was up 13.9% from 2023-12-31 to 2024-12-31. EQ currently screens at market cap $189.0M.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
EQ currently screens at market cap $189.0M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the EQ and REGN stock pages for the full models.
Not investment advice.